Science Explorer Back to mapMap
Discussion
Institution · Chugai Pharmaceutical Co., Ltd. (Japan)

Most cited papers from Chugai Pharmaceutical Co., Ltd. (Japan)

Chugai Pharmaceutical Co., Ltd. (Japan)

What are the most cited papers from Chugai Pharmaceutical Co., Ltd. (Japan)?

The most cited paper from Chugai Pharmaceutical Co., Ltd. (Japan) is "A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection" (Hiroshi I. Suzuki et al., 1997), with 1,229 citations. Next come "PrognoScan: a new database for meta-analysis of the prognostic value of genes" (1,074) and "Elevated blood pressure and craniofaclal abnormalities in mice deficient in endothelin-1" (994).

Showing 50 of 60 papers. Every paper with more than 171 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection Hiroshi I. Suzuki et al. · Nature Mar 1997 1,229
2 PrognoScan: a new database for meta-analysis of the prognostic value of genes Hideaki Mizuno, Kunio Kitada, Kenta Nakai et al. · BMC Medical Genomics ReviewOpen access 24 Apr 2009 1,074
3 Elevated blood pressure and craniofaclal abnormalities in mice deficient in endothelin-1 Yukiko Kurihara, Hiroki Kurihara, Hiroshi I. Suzuki et al. · Nature Apr 1994 994
4 Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway William A. Freed-Pastor, Hideaki Mizuno, Xi Wen Zhao et al. · Cell Open access 2012 874
5 Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology 27 Aug 2014 754
6 Impaired Pressure Sensation in Mice Lacking TRPV4 Makoto Suzuki, Atsuko Mizuno, Kunihiko Kodaira et al. · Journal of Biological Chemistry Open access Jun 2003 749
7 Translating IL-6 biology into effective treatments Ernest Choy, Fabrizio De Benedetti, Tsutomu Takeuchi et al. · Nature Reviews Rheumatology ReviewOpen access 23 Apr 2020 713
8 CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell Open access May 2011 636
9 CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study Takashi Seto, Katsuyuki Kiura, Makoto Nishio et al. · The Lancet Oncology 29 Apr 2013 579
10 An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitis Masahiko Matsumoto, Natsuko Hada, Yoshiyuki Sakamaki et al. · International Journal of Experimental Pathology Open access 11 Jan 2013 537
11 Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma Miwako Kakiuchi et al. · Nature Genetics 11 May 2014 515
12 Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo Hitoshi Saitô, Akira Maeda, Shuichi Ohtomo et al. · Journal of Biological Chemistry Open access 6 Nov 2004 473
13 1α,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells Chisato Miyaura, Etsuko Abe, Takeo Kuribayashi et al. · Biochemical and Biophysical Research Communications Oct 1981 459
14 Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. Toshimasa Tsujinaka, Junya Fujita, Chikara Ebisui et al. · Journal of Clinical Investigation Open access 1996 430
15 Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production Hitoshi Saitô, Kenichiro Kusano, Masahiko Kinosaki et al. · Journal of Biological Chemistry Open access 2003 420
16 A Resorcylic Acid Lactone, 5Z-7-Oxozeaenol, Prevents Inflammation by Inhibiting the Catalytic Activity of TAK1 MAPK Kinase Kinase Jun Ninomiya‐Tsuji, Taisuke Kajino, Koichiro Ono et al. · Journal of Biological Chemistry Open access May 2003 419
17 Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai et al. · Clinical Cancer Research 15 Aug 2005 395
18 Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) Yoshikazu Nakaoka, Mitsuaki Isobe, Syuji Takei et al. · Annals of the Rheumatic Diseases Open access 30 Nov 2017 391
19 Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases Mineto Ota et al. · Cell Open access May 2021 362
20 IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17 Misato Hashizume, Naohiko Hayakawa, Masahiko Mihara · Lara D. Veeken 13 Aug 2008 361
21 Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Tomoyuki Igawa et al. · Nature Biotechnology 17 Oct 2010 359
22 Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda et al. · PLoS ONE Open access 28 Feb 2013 338
23 Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family Masahiko Mihara, Keiko Kasutani, Makoto Okazaki et al. · International Immunopharmacology 22 Jun 2005 332
24 The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional Masami Hasegawa, Kenji Kawai, T Mitsui et al. · Biochemical and Biophysical Research Communications Open access 20 Jan 2011 320
25 Identification of an atypical monocyte and committed progenitor involved in fibrosis Takashi Satoh, Katsuhiro Nakagawa, Fuminori Sugihara et al. · Nature 20 Dec 2016 315
26 Mechanical Stretch Activates the JAK/STAT Pathway in Rat Cardiomyocytes Jing Pan, Keiichi Fukuda, Mikiyoshi Saito et al. · Circulation Research Open access 28 May 1999 315
27 Comparison of Various Submucosal Injection Solutions for Maintaining Mucosal Elevation During Endoscopic Mucosal Resection Mitsuhiro Fujishiro, Naohisa Yahagi, Koji Kashimura et al. · Endoscopy Jul 2004 300
28 The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group Khalid El Bairi et al. · npj Breast Cancer Open access554 authors Dec 2021 288
29 Oral Absorption of Poorly Water-Soluble Drugs: Computer Simulation of Fraction Absorbed in Humans from a Miniscale Dissolution Test Ryusuke Takano, Kiyohiko Sugano, Atsuko Higashida et al. · Pharmaceutical Research 20 May 2006 280
30 Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Koh Sato, Masayuki Tsuchiya, José W. Saldanha et al. · PubMed 15 Feb 1993 278
31 Reduced elimination of IgG antibodies by engineering the variable region Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana et al. · Protein Engineering Design and Selection 15 Feb 2010 266
32 A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects Naoki Uchida, Takehiko Sambe, Koichiro Yoneyama et al. · Blood Open access Dec 2015 262
33 Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial Yoshiaki Nakamura et al. · Nature Medicine Open access Nov 2021 245
34 Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases Tatsushi Kodama, Masami Hasegawa, Kenji Takanashi et al. · Cancer Chemotherapy and Pharmacology 9 Sep 2014 244
35 The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis Misato Hashizume, Masahiko Mihara · Arthritis Open access 26 May 2011 243
36 Cardiac p300 Is Involved in Myocyte Growth with Decompensated Heart Failure Tetsuhiko Yanazume, Koji Hasegawa, Tatsuya Morimoto et al. · Molecular and Cellular Biology Open access May 2003 238
37 Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist Takahiro Kawai, Bingfa Sun, Hitoshi Yoshino et al. · Proceedings of the National Academy of Sciences Open access 11 Nov 2020 226
38 Prediction of Sensitivity of Rectal Cancer Cells in Response to Preoperative Radiotherapy by DNA Microarray Analysis of Gene Expression Profiles Toshiaki Watanabe, Yasuhiro Komuro, Tomomichi Kiyomatsu et al. · Cancer Research Open access Apr 2006 226
39 Vitamin D Activates the Nrf2-Keap1 Antioxidant Pathway and Ameliorates Nephropathy in Diabetic Rats Kentaro Nakai, Hideki Fujii, Koji Kono et al. · American Journal of Hypertension 11 Sep 2013 219
40 An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors Takahiro Ishiguro et al. · Science Translational Medicine 4 Oct 2017 213
41 Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens Takehisa Kitazawa, Keiko Esaki, Tatsuhiko Tachibana et al. · Thrombosis and Haemostasis Open access 28 Apr 2017 209
42 Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody Danbee Ha, Atsushi Tanaka, Tatsuya Kibayashi et al. · Proceedings of the National Academy of Sciences Open access 26 Dec 2018 206
43 Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells Toshihiko Ohtomo, Yasuhiro Sugamata, Yasuko Ozaki et al. · Biochemical and Biophysical Research Communications May 1999 203
44 High Throughput Prediction of Oral Absorption: Improvement of the Composition of the Lipid Solution Used in Parallel Artificial Membrane Permeation Assay Kiyohiko Sugano, Hirokazu Hamada, Minoru Machida et al. · SLAS DISCOVERY Open access Jun 2001 202
45 INTERLEUKIN-6 (IL-6) INDUCES THE PROLIFERATION OF SYNOVIAL FIBROBLASTIC CELLS IN THE PRESENCE OF SOLUBLE IL-6 RECEPTOR Masahiko Mihara, Yoichiro Moriya, Tadamitsu Kishimoto et al. · Lara D. Veeken 1995 201
46 Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance Tatsushi Kodama, Toshiyuki Tsukaguchi, Miyuki Yoshida et al. · Cancer Letters 2 Jun 2014 200
47 First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma Andrew Xiuxuan Zhu, Philip Jordan Gold, Anthony B. El-Khoueiry et al. · Clinical Cancer Research Open access 30 Jan 2013 197
48 Dissolution Improvement and the Mechanism of the Improvement from Cocrystallization of Poorly Water-soluble Compounds Koji Shiraki, Noriyuki Takata, Ryusuke Takano et al. · Pharmaceutical Research 23 Jul 2008 196
49 The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co O. Nemoto, Masataka FURUE, Hidemi Nakagawa et al. · British Journal of Dermatology Open access 26 Sep 2015 194
50 Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients Takao Koike, Masayoshi Harigai, Shigeko Inokuma et al. · Annals of the Rheumatic Diseases Open access 18 Aug 2011 193

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.